Healthcare Triangle Signs Non-Binding LOI to Acquire 51% of CosmoInnovations; Enters High-Growth Proprietary MedTech and Consumer-Health Markets

Healthcare Triangle, Inc. (Nasdaq: HCTI), a provider of digital transformation solutions for the healthcare and life sciences industries, has signed a non-binding Letter of Intent to acquire a 51% equity stake in CosmoInnovations, a Melbourne-based innovator in MedTech and consumer health products. The proposed acquisition, valued at $23.5 million, marks a significant strategic move for Healthcare Triangle as it seeks to transition from a healthcare IT services provider to a product-led innovation platform.

CosmoInnovations operates under the brand CosmoAesthetics and boasts a diverse portfolio of proprietary technologies across high-growth sectors, including skincare, respiratory wellness, and pain management. The company holds 27 granted international patents and has 61 pending patent applications, providing a robust intellectual property foundation that Healthcare Triangle aims to leverage. CosmoInnovations is targeting over $50 million in cumulative revenue over the next three years, with an anticipated annualized run-rate of approximately $33 million by Year 3 post-acquisition, although these targets remain subject to achievement.

The acquisition aligns with Healthcare Triangle's strategic objectives to enhance its proprietary intellectual property and expand its offerings beyond traditional healthcare IT. By integrating CosmoInnovations' physical and medical technologies with its existing artificial intelligence and digital infrastructure, HCTI aims to establish a high-margin, recurring-revenue ecosystem that spans both clinical and consumer health sectors. This strategic pivot is expected to create new revenue streams through products such as SkinGate PODs and connected services, thereby diversifying HCTI's revenue base.

Moreover, the transaction positions Healthcare Triangle to capitalize on adjacent healthcare markets, including BeautyTech and home-based consumer care. The integration of CosmoInnovations' products into HCTI's technology infrastructure could facilitate manufacturing, distribution, and market entry, particularly in the U.S. market. CosmoInnovations has already established a manufacturing partnership with Shenzhen RedV Medical Equipment Co., Ltd., which has completed FDA establishment registration, indicating readiness to navigate regulatory pathways in the U.S.

In summary, this acquisition reflects broader trends in the MedTech and consumer health sectors, where companies are increasingly seeking to combine technology with innovative healthcare solutions. As Healthcare Triangle embarks on this new chapter, the successful integration of CosmoInnovations' assets could not only enhance its market position but also contribute to the evolution of a more interconnected healthcare ecosystem. The transaction underscores the growing emphasis on innovation and intellectual property in the MedTech space, setting the stage for future developments in both companies' growth trajectories.